Epidermal growth factor receptor (EGFR) as a specific therapeutic target in non small cell lung cancer;Recettore per il fattore di crescita epidermico (EGFR) come bersaglio terapeutico nelle neoplasie polmonari non a piccole cellule

Rassegna di Patologia dell'Apparato Respiratorio

Volumn 20, Issue 3, 2005, Pages 117-122

  Benedetti, Giovanni ^a   Bartolini, S ^a   Cappuzzo, F ^a   Rastelli, F ^a   Crino L ^a  

^a BELLARIA HOSPITAL   (Italy)

Author keywords

EGFR; Iressa; NSCLC; Tyrosin kinase

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSFORMING GROWTH FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG RESPONSE; DRUG TARGETING; GENE TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; REVIEW; SIGNAL TRANSDUCTION;

EID: 27944499427     PISSN: 00339563     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Perez-Soler R, Mendelsohn J. Growth factor receptors as target for therapy. In: Roth JA, Cox JD, Hong WK, eds. Lung Cancer. 2nd Edition. Malden, MA: Blackwell Science Inc. 1998.
2. Lodish H, Berk A, Lawrence S, Zipurdky P, Marsudaira D, Baltimore JD, et al. La comunicazione intracellulare: gli ormoni ed i recettori. In: Molecular Cell Biology. 4th Edition. New York: V.H. Freeman and Company 2000.
3. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
4. Baselga J, Mendelsohn J, Kim YM, Kim YM, Pandiella A. Autocrine regulation of membrane trasforming growth factor alfa cleavage. J Biol Chem 1996;271:3279-3284.
5. Yarden Y, Sliwkowski M. Untangling the erbb signaling network. Nat Rev Mol Cell Biol 2001;2:127-137.
6. Schlessinger J. Cell signaling by receptor Tyrosine Kinases. Cell 2000;103:211-225.
7. Lewis TS, Shapiro PS, Ahn NG. Signal trasduction through MAP kinase cascades. Adv Cancer Res 1998;74:49-139.
8. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
9. Aida S, Tamai S, Sekiguchi S, Shimizu N. Distribution of epidermal growth factor and epidermal growth factor receptor in human lung: immunohistochemical and immunoelectron-microscopic studies. Respiration 1994;61:161-166.
10. Kurie J, Shin HJ, Lee JS, Morice RC, Ro JY, Lippman SM, et al. Increased epideraml growth factor receptor expression in metaplastic bronchial epithelium. Cancer Res 1996;2:1787-1793.
11. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20(18):1s-13s.
12. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth factor receptors: a review of clinical research with focus on non small cell lung cancer. Lancet Oncology 2003;4:397-406.
13. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21(14):2787-2799.
14. Gatzemeier U, Rosell R, Ramlau R, Robinet G, Szczesna A, Quoix E, et al. Cetuximab (Erbitux) in combination with cisplatin/vinorelbine vs cisplatin/vinorelbine alone in the first-line treatment of patients with epidermal growth factor receptor-expressing advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2003;22:642(Abstr 2582).
15. Robert F, Blumenschein G, Dicke K, Tseng J, Saleh MN, Needle M. Phase IB/IIIA study of anti-epidermal growth factor receptor antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced stage IV non-small cell lung cancer. Proc Am Soc Clin Oncol 2003;22:643(Abstr 2587).
16. Kelly K, Hanna N, Rosenberg A, Bunn PA, Needle MN. A multicenter phase I/II study of anti-epidermal growth factor receptor antibody, cetuximab, in combination with paclitaxel and carboplatin in patients with IV non-small cell lung cancer. Proc Am Soc Clin Oncol 2003;22:644(Abstr 2592).
17. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, et al. Final results from a phase II trial of ZD1839 (Iressa) for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002;21:2989(Abstr 1188).
18. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr., Prager D, Belani CP, et al. A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002;21:2929(Abstr 1166).
19. Giaccone G, Johnson DH, Manegold C, Scagliotti GV, Rosell R, Wolf M, et al. A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitibine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1). Ann Oncol 2002;13:2(Abstr 40).
20. Johnson DH, Herbst R, Giaccone G, Schiller J, Natale RB, Miller V, et al. ZDD1839 (iressa) in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann Oncol 2002;13:127(Abstr 468).
21. Forero L, Patnaik A, Hammond LA, Tolcher A, Schwartz G, Hidalgo M, et al. Phase I, pharmacokinetic (PK) and biologic study of OS1774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin. Proc Am Soc Clin Oncol 2002;21:25b(Abstr 1908).
22. Green MR. Targeting targeted therapy. N Engl J Med 2004;20:2191-2193.